Page 2 - Pharmaceutical Companies

India pharma exports surge 9%, outpacing global average, says report

India has also surpassed the US in the number of FDA-registered generic manufacturing sites

Indian drugmakers bank on bilateral talks for relief from US tariffs

India, which calls itself the 'pharmacy of the world', makes cheaper generic versions of complex innovative drugs in its massive factory clusters and exports them to over 200 countries

Pharmaceutical companies, CDSCO to discuss regulatory matters on Friday

It is expected that representatives for MSMEs pharma manufacturers may raise the issue of extension of Revised Schedule M implementation timelines

Dr Reddy's Labs Q3 Preview: Revlimid to dent US sales, profits may rise 12%

Indian pharmaceutical (IT) major, Dr Reddy's Laboratories, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Thursday, January 23, 2025

Takeda opens Bengaluru ICC, targets 750 employees to boost India presence

The flagship ICC in Bengaluru complements Takeda's existing centres in Slovakia and Mexico, highlighting its strategic focus on data and advanced digital technologies

Senores gains 43% on stock market debut; Ventive up 10%, Carraro dips 10%

The listing day performance was largely in line with the subscription levels for the threen IPOs

Lupin acquires Huminsulin from Lilly to strengthen diabetes portfolio

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children

Healthcare sector in India to reach $320 billion by 2028, says report

India's pharmaceutical sector is targeting $130 billion by 2030 and biotechnology is aiming for $300 billion by the same year: Great Place To Work report

CRISIL analysis: Exports, domestic demand to drive pharma sector's growth

Bulk drug exports are expected to see moderate increases, supported by volume growth from new launches, customised synthesis, and rising demand for complex drugs

Despite short-term blip, Sun Pharma remains favourite among investors

According to Bloomberg, 30 of 41 analysts are bullish on Sun Pharma, while the remaining seven have a neutral rating and only 4 are bearish

NGT issues notice to environment ministry over Hyderabad pharma unit blast

The National Green Tribunal has sought a response from the Hyderabad regional office of the Union Ministry of Environment Forest and Climate Change and others on the blast at a pharmaceutical company in Hyderabad last month that left one dead and three others injured. The green body was hearing a matter where it had taken suo motu (on its own) cognisance of a PTI report published on November 21 titled 'One dead, three injured in reactor blast at pharma company in Hyderabad.' In an order dated November 28, a bench of NGT Chairperson Justice Prakash Shrivastava said, "The news item relates to a flash fire triggered by a reactor blast at a pharmaceutical company in Hyderabad, resulting in the death of one man and injuries caused to three others. As per the article, the incident occurred while the four workers were repairing the reactor." The bench also comprising judicial member Justice Arun Kumar Tyagi and expert member A Senthil Vel said the news item did not indicate whether steps h

Sun Pharma Q1 results: Profit zooms 40% on robust global specialty sales

On a sequential basis, the company exhibited a 6.8 per cent rise in net profit, while its revenue grew by 5.5 per cent, from Rs 2,655 crore and Rs 12,380.7 crore reported in Q3 FY24, respectively

Cipla Q1 Preview: Restructure in biz may dent sales; profits to rise 7%

Cipla is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year on year basis and net profits seeing a mid single digit growth

Indian pharma firms seek govt tax reliefs, incentives to spur innovation

The upcoming budget would be Modi's first major policy announcement in his third term as prime minister

Emcure Pharma seeks to raise Rs 1,952 cr through IPO, issue opens July 3

Fourth largest IPO of 2024; company will use the proceeds to repay debt and for general corporate purposes

Emcure Pharma, HDT settle legal fight over Covid vaccine technology

The companies said they have signed a long-term agreement to continue collaborating on the development of mRNA-based vaccines and a license that allows Emcure to use HDT's mRNA technology

Emcure, Gennova settle legal dispute with US-based HDT Bio, sign agreement

Litigation before courts in the US and arbitral tribunal in London settled, two sides say

Zydus, MSN partner to license, supply affordable cancer tablets in the US

MSN Lab will manufacture and supply Cabozantinib; Zydus will handle marketing, distribution and sales

India raises issue of pharma pricing control in Australia on generic drugs

India has raised the issue of pharmaceutical pricing control in Australia, particularly on generic medicines, during a recent bilateral meeting between the officials of the two countries. The two sides have decided to work closely on timely resolution of market access issues, deepen people-to-people contacts, and create an institutional mechanism for sharing of preferential import data, the commerce ministry said on Saturday. The bilateral trade between the countries declined 7.7 per cent to USD 24 billion in 2023-24 as against USD 26 billion in 2022-23. These issues among others were discussed during the first Joint Committee Meeting (JCM) in Canberra under India-Australia Economic Co-operation and Trade Agreement (Ind-Aus ECTA). "Both the sides while acknowledging the smooth implementation of the ECTA, briefly elaborated on ECTA implementation issues including MRAs (mutual recognition agreements) on organic products, market access issues related to products like okra, pomegranate

Lowering prices to weigh down earnings of Indian API players in near term

According to the brokerage, prices of APIs such as Paracetamol, Azithromycin, Montelukast, and Meropenem, have all declined in the range of 10-30 per cent over the last one year